Skip to content
Isopropamide
Darbid (isopropamide) is a small molecule pharmaceutical. Isopropamide was first approved as Darbid on 1982-01-01. It is used to treat biliary dyskinesia, cholelithiasis, diarrhea, duodenitis, and gastritis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isopropamide iodide
Tradename
Company
Number
Date
Products
DARBIDGSKN-010744 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
biliary dyskinesiaEFO_0007169D001657—
cholelithiasisEFO_0004799D002769K80
diarrheaHP_0002014D003967R19.7
duodenitis—D004382K29.8
gastritisEFO_0000217D005756K29.7
gastroenteritisEFO_1001463D005759K52.9
gastrointestinal diseases—D005767—
irritable bowel syndromeEFO_0000555D043183K58
peptic ulcerHP_0004398D010437K27
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03A: Drugs for functional gastrointestinal disorders
— A03AB: Synthetic anticholinergics, quaternary ammonium compounds for functional gastrointestinal disorders
— A03AB09: Isopropamide
— A03C: Antispasmodics in combination with psycholeptics
— A03CA: Synthetic anticholinergic agents in combination with psycholeptics
— A03CA01: Isopropamide and psycholeptics
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameISOPROPAMIDE
INNisopropamide iodide
Description
Isopropamide (R79) is a long-acting anticholinergic drug. It is used in the treatment of peptic ulcers and other gastrointestinal disorders involving hyperacidity (gastrointestinal acidosis) and hypermotility. Chemically, it contains a quaternary ammonium group. It is most often provided as an iodide salt, but is also available as a bromide or chloride salt. It was discovered at Janssen Pharmaceutica in 1954.
Classification
Small molecule
Drug classdiuretics (sulfamoylbenzoic acid derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C
Identifiers
PDB—
CAS-ID7492-32-2
RxCUI89784
ChEMBL IDCHEMBL1201232
ChEBI ID6043
PubChem CID3775
DrugBankDB01625
UNII IDE0KNA372SZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 84 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details